Mayo Clinic: Carcinoma, Renal Cell trials

The registry lists 14 Carcinoma, Renal Cell studies with Mayo Clinic as lead sponsor. 6 are open to participants now and 1 have results posted.

Early Phase 1 1Phase 1 3Phase 2 6No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07510334Phase 2
• The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
• Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney CancerNot yet recruitingNCT07243067
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic PlatformRecruitingNCT06349642
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramRecruitingNCT06265285Phase 2
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingNCT05269381Phase 1/2
• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney CancerCompletedNCT01767636Phase 2Results posted
• Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE StudyCompletedNCT06339138
• Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative TherapyCompletedNCT05112627
• TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsTerminatedNCT02650635Phase 1
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsCompletedNCT02646319Early Phase 1
• Renal Mass RegistryCompletedNCT01887574Not applicable
• Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedNCT00655655Phase 1
• Dolastatin 10 in Treating Patients With Advanced Kidney CancerCompletedNCT00003914Phase 2